Z-0318-06
EnVision+, an ImmunoHistoChemistry reagent. This in-vitro diagnostic (reagent) is marketed both as a...
Agilent Technologies, Inc. / initiated 2005-10-14 / Terminated
Dakocytomation California Inc began a recall of EnVision+, an ImmunoHistoChemistry reagent. This in-vitro diagnostic (reagent) is marketed both as a component in various finished assay kits and as a... on . The reason FDA records is "This recall has been initiated due to a formulation error in the EnVision+ visualization reagent". As of , the recall status on record is Terminated.
Recall record
- Recall number
- Z-0318-06
- Status
- Terminated
- Initiated
- Posted
- Terminated
- Recalling firm
- Agilent Technologies, Inc.
- Product
- EnVision+, an ImmunoHistoChemistry reagent. This in-vitro diagnostic (reagent) is marketed both as a component in various finished assay kits and as a standalone product. Model Number K4009
- Product code
- NJT Immunohistochemistry Reagents And Kits
- Reason for recall
- This recall has been initiated due to a formulation error in the EnVision+ visualization reagent.
- FDA root cause
- Other
- Action
- Notification letter dated October 14, 2005 was sent by certified mail to cosignees instructing dosposal of product.
- Quantity in commerce
- Lots 045175=14, 065144=6 &, 085147=0
- Distribution
- Nationwide to: AK, AL, AZ, CA, CO, CT, DC, FL, GA, HI, IA, IL, IN, KS, KY, LA, MA, MD, MI, MO, MN, NC, NE, NJ, NY, OH, OK, OR, PA, RI, SC, SD, TN, TX, VA, VT, WA, WI, and WV. Worldwide to: Argentina, Bermuda, Brazil, Canada, Costa Rica, Denmark, Japan, Mexico, New Zealand, and Uruguay.
- Product codes and lots
- K4009: Lots 045175, 065144, 085147
FIRST ARTICLE / WEEKLY
What cleared, what was recalled, and what changed in the standards. One edition a week for the people who make medical devices.
